Redman Andrea R, Ryan Gina J
Department of Clinical and Administrative Sciences, Mercer University Southern School of Pharmacy, 3001 Mercer University Drive, Atlanta, GA 30341, USA.
Expert Opin Pharmacother. 2004 Jan;5(1):117-23. doi: 10.1517/14656566.5.1.117.
Stroke is the third leading cause of death in the US with recurrent events a high likelihood in those who survive an initial event. The long-term goal of therapy is to prevent the recurrence of stroke and other atherosclerotic events. Aspirin has been the first-line agent for stroke prevention for a long time. As new antiplatelet agents have been introduced, their role in the secondary prevention of stroke remains to be defined. In particular, the role of the combination of aspirin and modified-release dipyridamole (Aggrenox, Boehringer Ingelheim Corp.), the newest product, in the secondary prevention of stroke, remains unknown. The purpose of this manuscript is to review the evidence of these antiplatelet agents in the secondary prevention of stroke and arrive at a conclusion specifically regarding the role of Aggrenox. Clinical studies which examined stroke as a single primary outcome or as one event in a combined primary outcome will be reviewed.
中风是美国第三大死因，初次中风存活者很可能再次发病。治疗的长期目标是预防中风复发及其他动脉粥样硬化事件。长期以来，阿司匹林一直是预防中风的一线药物。随着新型抗血小板药物的问世，它们在中风二级预防中的作用仍有待明确。特别是最新产品阿司匹林与缓释双嘧达莫（Aggrenox，勃林格殷格翰公司）联合用药在中风二级预防中的作用尚不清楚。本文的目的是回顾这些抗血小板药物在中风二级预防中的证据，并就Aggrenox的作用得出具体结论。将对把中风作为单一主要结局或作为联合主要结局中的一个事件进行研究的临床研究进行综述。
